| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | 1 | 1 | 1 | 1 | 2 | 1 | — | 5 | 1 | 1 | 1 | — |
| total | individual payouts | |
|---|---|---|
| 2028 | ‡‡‡ |
|
| 2027 | ‡‡‡‡ |
|
| 2026 | 1.24 |
—
—
—
|
| 2025 | 1.20 |
—
—
—
—
|
| 2024 | 1.12 |
—
—
—
—
|
| 2023 | 1.04 |
—
—
—
—
|
| 2022 | 0.96 |
—
—
—
—
|
| 2021 | 0.80 |
—
—
—
—
|
| 2020 | 0.76 |
—
—
—
—
|
| 2019 | 0.64 |
—
—
—
—
|
| 2018 | 0.46 |
—
—
—
—
|
| 2017 | 0.42 |
—
—
—
—
|
| 2016 | 0.36 |
—
—
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 187.15 | 258.90 | 221.93 | 66.63 |
| Receivables | 167.36 | 161.41 | 181.51 | 218.50 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 379.53 | 446.88 | 427.58 | 312.01 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 22.13 | 22.14 | 30.94 | 26.94 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 161.91 | 163.18 | 178.00 | 157.84 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 166.30 | 171.61 | — | — |
—
|
| ’25 | 145.51 | 141.96 | 147.12 | 147.43 |
582.01
|
| ’24 | 144.93 | 140.54 | 136.28 | 136.77 |
558.51
|
| ’23 | 140.31 | 140.22 | 133.34 | 122.90 |
536.77
|
| ’22 | 128.48 | 130.28 | 127.18 | 127.36 |
513.29
|
| ’21 | 116.48 | 119.88 | 116.41 | 113.51 |
466.27
|
| ’20 | 105.95 | 92.05 | 98.66 | 103.24 |
399.90
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.97) | 30.89 | — | — |
—
|
| ’25 | 7.27 | 36.22 | 32.65 | 55.58 |
131.73
|
| ’24 | 10.43 | 48.34 | 29.71 | 56.05 |
144.54
|
| ’23 | (6.70) | 40.55 | 22.20 | 71.31 |
127.35
|
| ’22 | (6.35) | 30.17 | 29.42 | 40.57 |
93.81
|
| ’21 | 1.29 | 44.17 | 24.93 | 54.19 |
124.57
|
| ’20 | (13.83) | 48.03 | 28.25 | 40.87 |
103.31
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.43) | 29.11 | — | — |
—
|
| ’25 | 5.52 | 33.95 | 29.98 | 52.90 |
122.34
|
| ’24 | 8.95 | 47.19 | 28.00 | 53.46 |
137.60
|
| ’23 | (12.37) | 35.10 | 18.90 | 69.38 |
111.00
|
| ’22 | (8.96) | 26.86 | 26.23 | 37.64 |
81.76
|
| ’21 | (1.23) | 42.44 | 23.74 | 52.80 |
117.74
|
| ’20 | (15.13) | 46.86 | 26.57 | 40.02 |
98.33
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.59 | 0.60 | — | — |
—
|
| ’25 | 0.52 | 0.52 | 0.55 | 0.49 |
2.07
|
| ’24 | 0.59 | 0.57 | 0.50 | 0.46 |
2.11
|
| ’23 | 0.56 | 0.50 | 0.48 | 0.41 |
1.94
|
| ’22 | 0.56 | 0.49 | 0.47 | 0.44 |
1.96
|
| ’21 | 0.58 | 0.48 | 0.46 | 0.38 |
1.90
|
| ’20 | 0.49 | 0.31 | 0.34 | 0.41 |
1.55
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 80.97 | 64.61 | 68.70 | 63.81 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 118.93 | 112.75 | 115.75 | 97.57 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,313 | 1,320 | 1,168 | 1,212 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.39 | 0.41 | 0.48 | 0.48 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 513.29 | 536.77 | 558.51 | 582.01 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 90.36% | 92.63% | 92.83% | 92.22% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 132.23 | 135.90 | 147.37 | 147.30 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 25.76% | 25.32% | 26.39% | 25.31% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 102.33 | 100.34 | 109.00 | 106.01 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.08 | 8.92 | 9.69 | 10.08 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.92 | 10.49 | 10.92 | 11.43 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 1.98 | 1.96 | 2.13 | 2.08 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.81 | 2.49 | 2.83 | 2.59 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.23) | (0.32) | (0.14) | (0.18) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.58 | 2.17 | 2.69 | 2.40 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.20 | 6.96 | 8.24 | 7.67 | ‡‡‡‡ | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 51.73 | 51.15 | 51.13 | 50.90 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 50.35 | 46.38 | 41.83 | 33.39 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.00 | 8.66 | 8.16 | 6.08 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.00 | 13.06 | 10.82 | 9.06 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.72 | 8.37 | 7.74 | 5.74 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 61.00 | 40.46 | 31.43 | 27.31 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 93.81 | 127.35 | 144.54 | 131.73 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.04) | (16.36) | (6.94) | (9.39) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 81.76 | 111.00 | 137.60 | 122.34 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 190.13 | 217.62 | 283.70 | 249.58 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.60 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (142.86) | (187.15) | (258.90) | (221.93) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 320.75 | 356.09 | 421.07 | 390.34 | — | — | — |
Sh' Equity
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.11% | 16.27% | 15.31% | 13.64% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 49.48% | 41.19% | 46.08% | 44.45% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 27.74% | 29.65% | 28.05% | 26.13% | — | — | — |
ROE
|
Exponent, Inc. (EXPO), a niche powerhouse in engineering and scientific consulting, has delivered resilient growth over the past decade, with revenue surging 77% from $315 million in 2016 to $558 million in 2024 at a 7.4% CAGR, fueled by demand in failure analysis, regulatory work, and expert testimony. Revenue per employee soared 55% to $478,000 amid stable headcount, while gross margins held near 93%, EBT margins expanded to 26.4%, and ROE averaged over 25%—far superior to peers—driving FCF per share to $2.69 in 2024 and a fortress balance sheet with -$259 million net debt.
Yet, the stock trades at a 32% discount to recent highs, with PS at 8.2x and EV/FCF at 31x, decoupling from fundamentals like 9% revenue growth and signaling market doubt amid inflation and rate hikes. Analyst forecasts eye 5% revenue CAGR through 2027, EPS up 11% to $2.52, and 27-50% upside to price targets, underpinned by a recession-resistant moat in litigation services.
Insider selling persists without buys, and correlations flag risks like margin dips tanking the stock 36% in 2022, but with ROIC over 44%, net cash buffers, and historical compounding outpacing shares, EXPO’s undervaluation screams mean reversion potential—unless talent wars or litigation cycles derail the party.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.